Principal Scientist
Amgen
South San Francisco, California
Colin Castleberry is a principal scientist in Amgen's quantitative pharmacology group within their PKDM department, and he is passionate about developing computational tools to drive decisions in biomedical research and advance medicine.
Colin has gained 9 years of biopharmaceutical modeling experience in both industry and academia. He primarily focuses on supporting drug development for large molecule and RNA therapeutics programs and has helped drive strategy and decision making for programs in the oncology, cardiometabolic disease, and rare disease therapeutic areas. Prior to Colin's work at Amgen, he worked as a biotechnology researcher with AbbVie as he completed his graduate studies. Colin is a systems biologist by training and was awarded a PhD in Bioengineering from the University of Illinois at Urbana Champaign in 2022.
Colin is also a passionate teacher and mentor, and has performed research in the engineering education domain to facilitate adaptive teaching and adaptive assessment in higher education courses.
Disclosure information not submitted.
Hot Topic: New Technologies and Approaches for Translation to Clinical Practice
Tuesday, November 11, 2025
2:30 PM - 3:30 PM CT